KESIMPTA resources
Don’t miss out on these resources to support you and your patients.
KESIMPTA®▼ (ofatumumab) Prescribing information (external link)
GILENYA® (fingolimod) Prescribing information (external link)
MAYZENT® (siponimod) Prescribing information (external link)
Image
Image
MS Insights Hub: Expert Perspectives
KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1
For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).1
GILENYA® is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for the following groups of adult patients and paediatric patients aged 10 years and older:
Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy, or
Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by two or more disabling relapses in one year, and with one or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI
For full safety information, please refer to the GILENYA Summary of Product Characteristics.2
MAYZENT® is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
For full safety information, please refer to the MAYZENT Summary of Product Characteristics.3
Meet the Experts
Dr Karen Chung, MS specialist and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery in London, discusses the critical role of shared decision‑making in MS care.
Click here to watch the video
Dr David Rog, Consultant Neurologist at Greater Manchester Hospital, shares expert insights into the evolving treatment goals for patients with active RMS, drawing on his extensive clinical experience in MS management.
Click here to watch the video
Image
The role of shared decision making and patient preferences in MS treatment choices
Dr Karen Chung, Consultant Neurologist at the National Hospital for Neurology and Neurosurgery in London, discusses her approach to shared decision making, when picking a disease-modifying therapy with her patients with MS. In this video, she highlights the revised criteria for MS diagnosis and treatment, the importance of considering the patient’s holistic needs when selecting a treatment and reflects on her clinical experience with KESIMPTA.
An overview of how treatment goals in active RMS have broadened to include markers of neuroinflammatory activity and progression
Dr David Rog, Consultant Neurologist at Greater Manchester Hospital, shares his perspectives on how the treatment of MS has changed over the course of his clinical practice. In this video, he discusses his expectations for high-efficacy therapy, the shift to expand goals beyond reducing annualised relapse rate, the insights provided by the KESIMPTA clinical trials and his own experience using the therapy in practice.
MS, multiple sclerosis; RMS, relapsing multiple sclerosis; RRMS, relapsing remitting multiple sclerosis; SmPC, summary of product characteristics; SPMS, secondary progressive multiple sclerosis.
Reference
KESIMPTA (ofatumumab) Summary of Product Characteristics.
GILENYA (fingolimod) Summary of Product Characteristics.
MAYZENT (siponimod) Summary of Product Characteristics.
UK | April 2026 | FA-11628342
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
